Journal of Clinical Endocrinology & Metabolism, Vol 78, 1378-1383, Copyright © 1994 by Endocrine Society

ARTICLES

Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia

TO Carpenter, MA Mitnick, A Ellison, C Smith and KL Insogna
Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut 06520-8064.

Parathyroid function is described as normal in patients with phosphopenic rickets before initiation of therapy with phosphate salts; however, hyperparathyroidism is an occasional complication of treatment. We observed a higher than expected frequency of hyperparathyroidism in patients with phosphate-wasting rickets, present before treatment in some patients and, more frequently, after the onset of treatment. To better define parathyroid status in hypophosphatemic rickets, we sampled 12 affected children and 7 affected adults every 4 h for 1 day and measured PTH in assays detecting midmolecule fragments (cPTH) and intact hormone (iPTH). All children and 4 adults were receiving a vitamin D preparation and phosphate salts; 3 adults were untreated. Mean cPTH, iPTH, and nephrogenous cAMP excretions in each group of patients were greater than in controls. Exaggerated nocturnal rises in both cPTH and iPTH characterized the profile in patients. Seventeen patients demonstrated frankly elevated cPTH at night, with peak values at midnight, whereas no control individual did. Although mean iPTH values in patients increased at night, they did not exceed the upper limit of normal. Hyperparathyroidism in hypophosphatemic rickets occurs in both children and adults, may be present in untreated patients, is predominantly nocturnal, and is characterized by exaggerated secretion of midmolecule fragments. This manifestation of hypophosphatemic rickets is more widespread than currently recognized; we speculate that it may contribute to the pathogenesis of nephrocalcinosis and precede the development of tertiary hyperparathyroidism.

This article has been cited by other articles:

				X. Bai, D. Miao, D. Goltzman, and A. C. Karaplis Early Lethality in Hyp Mice with Targeted Deletion of Pth Gene Endocrinology, October 1, 2007; 148(10): 4974 - 4983. [Abstract] [Full Text] [PDF]

				T. O. Carpenter, M. C. DeLucia, J. H. Zhang, G. Bejnerowicz, L. Tartamella, J. Dziura, K. F. Petersen, D. Befroy, and D. Cohen A Randomized Controlled Study of Effects of Dietary Magnesium Oxide Supplementation on Bone Mineral Content in Healthy Girls J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4866 - 4872. [Abstract] [Full Text] [PDF]

				R.J. MacIsaac, C. Tsalamandris, S. Panagiotopoulos, T.J. Smith, K.J. McNeill, G. Jerums, X Bai, D. Miao, J. Li, D. Goltzman, et al. Type 2 Diabetes: Absence of Proteinuria Does Not Preclude Loss of Renal Function: Nonalbuminuric Renal Insufficiency in Type 2 Diabetes. Diabetes Care 27: 195-200, 2004 J. Am. Soc. Nephrol., February 1, 2005; 16(2): 284 - 290. [Full Text] [PDF]

				X. Bai, D. Miao, J. Li, D. Goltzman, and A. C. Karaplis Transgenic Mice Overexpressing Human Fibroblast Growth Factor 23 (R176Q) Delineate a Putative Role for Parathyroid Hormone in Renal Phosphate Wasting Disorders Endocrinology, November 1, 2004; 145(11): 5269 - 5279. [Abstract] [Full Text] [PDF]

				M. C. DeLucia, M. E. Mitnick, and T. O. Carpenter Nutritional Rickets with Normal Circulating 25-Hydroxyvitamin D: A Call for Reexamining the Role of Dietary Calcium Intake in North American Infants J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3539 - 3545. [Abstract] [Full Text] [PDF]

				R. Nehgme, J. T. Fahey, C. Smith, and T. O. Carpenter Cardiovascular Abnormalities in Patients with X-Linked Hypophosphatemia J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2450 - 2454. [Abstract] [Full Text] [PDF]